BACKGROUND: The major route of folate turnover is by catabolic cleavage of the C9-N10 bond producing p-aminobenzoylglutamate (pABG) and its primary excretory form, p-acetamidobenzoylglutamate (ApABG). We hypothesize that total pABG (ApABG + pABG) excretion parallels both the mass of body folate pools from which these catabolites originate and the folate-status indicators. OBJECTIVE: The objective was to determine whether urinary folate catabolite excretion reflects body pool size and parallels the static and functional measures of folate status. DESIGN:Urinary folate catabolite excretion was measured in women (aged 60-85 y) consuming controlled amounts of folate for 14 wk. A low-folate diet (120 microg/d) was consumed (n = 33) for 7 wk, and then subjects were randomly assigned to consume either 200 (n = 14) or 400 (n = 16) microg folate/d. Urinary pABG and ApABG concentrations were measured by HPLC at 0, 7, and 14 wk. RESULTS:Urinary excretion of total pABG was significantly lower (P = 0.001) after depletion (73.9 +/- 4.7 nmol/d) than at baseline (115 +/- 12.7 nmol/d). This rate of decline (approximately 0.7% per day) is consistent with the kinetically measured rate of turnover of total body folate at moderate folate intakes. The average percentage increase in total pABG in response to folate repletion with 400 microg/d (75%) was significant (P = 0.02). Folate catabolite excretion was significantly (P = 0.0001) associated with serum and red blood cell folate, plasma homocysteine, and DNA hypomethylation after depletion and with serum folate (P = 0.001) and plasma homocysteine (P = 0.0002) after repletion with 400 microg folate/d. CONCLUSIONS: Total urinary pABG excretion reflects total body folate pool size and is a long-term indicator that parallels functional measures of folate status.
RCT Entities:
BACKGROUND: The major route of folate turnover is by catabolic cleavage of the C9-N10 bond producing p-aminobenzoylglutamate (pABG) and its primary excretory form, p-acetamidobenzoylglutamate (ApABG). We hypothesize that total pABG (ApABG + pABG) excretion parallels both the mass of body folate pools from which these catabolites originate and the folate-status indicators. OBJECTIVE: The objective was to determine whether urinary folate catabolite excretion reflects body pool size and parallels the static and functional measures of folate status. DESIGN: Urinary folate catabolite excretion was measured in women (aged 60-85 y) consuming controlled amounts of folate for 14 wk. A low-folate diet (120 microg/d) was consumed (n = 33) for 7 wk, and then subjects were randomly assigned to consume either 200 (n = 14) or 400 (n = 16) microg folate/d. Urinary pABG and ApABG concentrations were measured by HPLC at 0, 7, and 14 wk. RESULTS: Urinary excretion of total pABG was significantly lower (P = 0.001) after depletion (73.9 +/- 4.7 nmol/d) than at baseline (115 +/- 12.7 nmol/d). This rate of decline (approximately 0.7% per day) is consistent with the kinetically measured rate of turnover of total body folate at moderate folate intakes. The average percentage increase in total pABG in response to folate repletion with 400 microg/d (75%) was significant (P = 0.02). Folate catabolite excretion was significantly (P = 0.0001) associated with serum and red blood cell folate, plasma homocysteine, and DNA hypomethylation after depletion and with serum folate (P = 0.001) and plasma homocysteine (P = 0.0002) after repletion with 400 microg folate/d. CONCLUSIONS: Total urinary pABG excretion reflects total body folate pool size and is a long-term indicator that parallels functional measures of folate status.
Authors: Lisa A Houghton; Andrew R Gray; Meredith C Rose; Jody C Miller; Nicola A Hurthouse; Jesse F Gregory Journal: Am J Clin Nutr Date: 2011-05-18 Impact factor: 7.045
Authors: Padma Maruvada; Patrick J Stover; Joel B Mason; Regan L Bailey; Cindy D Davis; Martha S Field; Richard H Finnell; Cutberto Garza; Ralph Green; Jean-Louis Gueant; Paul F Jacques; David M Klurfeld; Yvonne Lamers; Amanda J MacFarlane; Joshua W Miller; Anne M Molloy; Deborah L O'Connor; Christine M Pfeiffer; Nancy A Potischman; Joseph V Rodricks; Irwin H Rosenberg; Sharon A Ross; Barry Shane; Jacob Selhub; Sally P Stabler; Jacquetta Trasler; Sedigheh Yamini; Giovanna Zappalà Journal: Am J Clin Nutr Date: 2020-11-11 Impact factor: 7.045
Authors: Lynn B Bailey; Patrick J Stover; Helene McNulty; Michael F Fenech; Jesse F Gregory; James L Mills; Christine M Pfeiffer; Zia Fazili; Mindy Zhang; Per M Ueland; Anne M Molloy; Marie A Caudill; Barry Shane; Robert J Berry; Regan L Bailey; Dorothy B Hausman; Ramkripa Raghavan; Daniel J Raiten Journal: J Nutr Date: 2015-06-03 Impact factor: 4.798
Authors: Anne J M R Geijsen; Arve Ulvik; Biljana Gigic; Dieuwertje E Kok; Fränzel J B van Duijnhoven; Andreana N Holowatyj; Stefanie Brezina; Eline H van Roekel; Andreas Baierl; Michael M Bergmann; Jürgen Böhm; Martijn J L Bours; Hermann Brenner; Stéphanie O Breukink; Mary P Bronner; Jenny Chang-Claude; Johannes H W de Wilt; William M Grady; Thomas Grünberger; Tanja Gumpenberger; Esther Herpel; Michael Hoffmeister; Lyen C Huang; Jolanta D Jedrzkiewicz; Eric T P Keulen; Rama Kiblawi; Torsten Kölsch; Janna L Koole; Katharina Kosma; Ewout A Kouwenhoven; Flip M Kruyt; Gry Kvalheim; Christopher I Li; Tengda Lin; Jennifer Ose; T Bartley Pickron; Courtney L Scaife; Peter Schirmacher; Martin A Schneider; Petra Schrotz-King; Marie C Singer; Eric R Swanson; Peter van Duijvendijk; Henk K van Halteren; Moniek van Zutphen; Kathy Vickers; F Jeroen Vogelaar; Evertine Wesselink; Nina Habermann; Alexis B Ulrich; Per M Ueland; Matty P Weijenberg; Andrea Gsur; Cornelia M Ulrich; Ellen Kampman Journal: JNCI Cancer Spectr Date: 2020-07-07
Authors: Mareile Niesser; Hans Demmelmair; Thea Weith; Diego Moretti; Astrid Rauh-Pfeiffer; Marola van Lipzig; Wouter Vaes; Berthold Koletzko; Wolfgang Peissner Journal: PLoS One Date: 2013-02-14 Impact factor: 3.240